A method of producing an implant for fecal transplant (FT), including: introducing fecal materials into a container, and processing the fecal materials to a smaller size in the container. According to some embodiments, the container is in ambient conditions, and the processing in the container includes non-ambient conditions. Optionally, the non-ambient conditions include an atmosphere having at most 18% of O.sub.2. Optionally, the method includes adding a liquid into the container, the liquid including a preservative material. Optionally, the liquid includes between 10% to 30% glycerol by volume. Optionally, the method includes sealing the container with a sealing lid after the introducing, and processing the fecal materials in the sealed container. Optionally, the processing of the fecal materials includes cutting the fecal materials by a cutting element to increase an exposed surface area of the fecal materials.

A method of producing an implant for fecal transplant (FT), including: introducing fecal materials into a container, and processing the fecal materials to a smaller size in the container. According to some embodiments, the container is in ambient conditions, and the processing in the container includes non-ambient conditions. Optionally, the non-ambient conditions include an atmosphere having at most 18% of O.sub.2. Optionally, the method includes adding a liquid into the container, the liquid including a preservative material. Optionally, the liquid includes between 10% to 30% glycerol by volume. Optionally, the method includes sealing the container with a sealing lid after the introducing, and processing the fecal materials in the sealed container. Optionally, the processing of the fecal materials includes cutting the fecal materials by a cutting element to increase an exposed surface area of the fecal materials.

A method and composition are provided for soil remediation. A method is provided for breaking down an organic chemical agent, comprising providing a plurality of sporulated microbes to the chemical agent. A composition is provided for breaking down an organic chemical agent, comprising a plurality of sporulated microbes.

A method and composition for treating drinking water for animals is disclosed. A method for treating drinking water for animals includes providing a plurality of sporulated microbes to metabolize an organic matter in the drinking water. A composition for treating animal drinking water includes a plurality of sporulated microbes.

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. This application provides novel compositions and methods for treating various disorders or conditions that are associated with a dysfunctional intestinal microbiota. In particular, this application provides compositions and methods that can treat or cure gastrointestinal (GI) disorders such as Inflammatory Bowel Disease (IBD), including, for example, Crohn's Disease and ulcerative colitis.

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. This application provides novel compositions and methods for treating various disorders or conditions that are associated with a dysfunctional intestinal microbiota. In particular, this application provides compositions and methods that can treat or cure gastrointestinal (GI) disorders such as Inflammatory Bowel Disease (IBD), including, for example, Crohn's Disease and ulcerative colitis.

The use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.

The use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.